Peptides and peptidomimetics as therapeutic agents for Covid-19

Authors

Achyut Dahal, School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy University of Louisiana at Monroe Monroe Louisiana USA.
Jafrin Jobayer Sonju, School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy University of Louisiana at Monroe Monroe Louisiana USA.
Konstantin G. Kousoulas, Department of Pathobiological Sciences, School of Veterinary Medicine Louisiana State University Baton Rouge Louisiana USA.
Seetharama D. Jois, School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy University of Louisiana at Monroe Monroe Louisiana USA.

Document Type

Article

Publication Date

1-1-2022

Abstract

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Covid-19 pandemic has caused high morbidity and mortality rates worldwide. Virus entry into cells can be blocked using several strategies, including inhibition of protein-protein interactions (PPIs) between the viral spike glycoprotein and cellular receptors, as well as blocking of spike protein conformational changes that are required for cleavage/activation and fusogenicity. The spike-mediated viral attachment and entry into cells via fusion of the viral envelope with cellular membranes involve PPIs mediated by short peptide fragments exhibiting particular secondary structures. Thus, peptides that can inhibit these PPIs may be used as potential antiviral agents preventing virus entry and spread. This review is focused on peptides and peptidomimetics as PPI modulators and protease inhibitors against SARS-CoV-2.

Publication Source (Journal or Book title)

Peptide science (Hoboken, N.J.)

First Page

e24245

Recommended Citation

Dahal, A., Sonju, J. J., Kousoulas, K. G., & Jois, S. D. (2022). Peptides and peptidomimetics as therapeutic agents for Covid-19. Peptide science (Hoboken, N.J.), 114 (1), e24245. https://doi.org/10.1002/pep2.24245